Save time and jump to the most important pieces.
PHOENIX, March 31, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a pioneer in fertility control solutions for managing rodent populations, today announced that it will participate in a webcast fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit, taking place virtually on Tuesday, April 1, 2025. The fireside chat will take place at 3:00 p.m. ET on Tuesday, April 1, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/ibmsummit25/ or directly at https:/
Company announces new operating optimization initiatives to reduce expenses by approximately $2 million to accelerate path to profitability PHOENIX, March 12, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a pioneer in fertility control solutions for managing rodent populations, today announced fourth quarter and full year 2024 financial results. Q4 2024 Highlights Revenue increased 70% to $501,000 in Q4 2024 compared to $295,000 in Q4 2023, led by growth in e-commerce which increased 206%.Gross profit margin percentage improved to 60
PHOENIX, March 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a pioneer in fertility control solutions for managing rodent populations, announced today the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 374,718 shares of the Company's common stock originally issued by the Company on August 23, 2024, each having an original exercise price of $4.35 per share, at a reduced exercise price of $2.90 per share. In addition, the Company will issue new short-term warrants, as described below. The closing of the warrant exercise transaction is expected to occur on or about March 11,
Company announces new operating optimization initiatives to reduce expenses by approximately $2 million to accelerate path to profitability PHOENIX, March 12, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a pioneer in fertility control solutions for managing rodent populations, today announced fourth quarter and full year 2024 financial results. Q4 2024 Highlights Revenue increased 70% to $501,000 in Q4 2024 compared to $295,000 in Q4 2023, led by growth in e-commerce which increased 206%.Gross profit margin percentage improved to 60
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, March 6, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its fourth quarter and fiscal year 2024, ended December 31, 2024, after the market close on Wednesday, March 12, 2025. The Company has scheduled a conference call that same day, Wednesday, March 12, 2025, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call Details Date and Time: Wednesday, March 12, 2025, at 5:00 pm ET Call-in Information: I
Record Revenue and Margin Performance PHOENIX, Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), the leader in fertility control to manage animal pest populations and the only manufacturer of commercial and consumer available EPA-registered Rat Birth Control® products today announced financial results for the third quarter of 2024. Recent Highlights Revenues of $1.4 million in the first nine months of 2024, an increase of 51% compared to the same period of 2023.Gross margin percentages improved to 65% during Q3 2024 compared to
4 - SenesTech, Inc. (0001680378) (Issuer)
3 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
D - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G - SenesTech, Inc. (0001680378) (Subject)
PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye
PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.